1453208-75-7

Upstream product

• 651734-55-3 methyl 2,6-difluoro-3,5-dimethoxybenzoate 
• 2150-37-0 methyl 3,5-dimethoxybenzoate 
• 16153-81-4 4-(4-Methyl-piperazino)-anilin 
• 1453211-61-4 2-chloro-5-[(2,6-difluoro-3,5-dimethoxyphenyl)methoxy]pyrimidine 
• 1453211-60-3 (2,6-difluoro-3,5-dimethoxyphenyl)methyl methanesulfonate 
• 1208434-90-5 (2,6-difluoro-3,5-dimethoxyphenyl)methanol 

Relevant academic research and scientific papers

Methods for detecting FGFR3/TACC3 fusion genes

[Problem] The present invention aims to elucidate a polynucleotide as a novel responsible gene for cancer and aims to thus provide a method for detecting the polynucleotide and a polypeptide encoded by the polynucleotide and a detection kit, a probe set,

PHARMACEUTICAL COMPOSITION HAVING PYRIMIDINE COMPOUND AS ACTIVE INGREDIENT

[Problem] A pharmaceutical composition for treating FGFR4-related cancer, FGF 19-related cancer, or FGF19 gene amplification-positive liver cancer is provided. [Means for Solution] The present inventors have investigated a compound having an inhibitory ac

NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND

Provided is a compound useful as a prophylactic and/or therapeutic agent for bladder cancer. As a result of studies on compounds having FGFR inhibitory action, the present inventors have found that the nitrogen-containing aromatic heterocyclic compounds of the present invention have inhibitory action on FGFR1, FGFR2, and/or FGFR3, particularly, mutant FGFR3, and thus, the present invention has been accomplished. The nitrogen-containing aromatic heterocyclic compound of the present invention can be used as a therapeutic agent for various cancers related to FGFR1, FGFR2, and/or FGFR3, such as lung cancer and hormone therapy-resistant breast cancer, stomach cancer, triple negative breast cancer, endometrial cancer, bladder cancer, and glioblastoma, particularly as a prophylactic and/or therapeutic agent for mutant FGFR3-positive bladder cancer.